Medical Devices: Licences, Production and Export Orders
The medical device division has recorded a significant improvement in sales and profitability across domestic and institutional channels. The company has secured 26 additional IVD medical device manufacturing licences, widening the range of products it can make and sell.
Production of AI-based dialysis machines has commenced at the Bengaluru facility. Trials began in November 2026 at specialised healthcare centres and with domestic customers, export orders are in hand, and machines are in final-stage of testing ahead of shipments from the end of December 2026 to the UK, USA, Africa, Nepal and Bangladesh as outright machine sales.
New-Generation Diagnostics and Therapies
Sickle Cell screening: all regulatory approvals are in place; commercial launch follows the manufacturing licence, expected in January 2027.
Breast cancer screening device: all regulatory approvals received; mass screening launch scheduled for January 2027.
AI-based medical devices: a suite for clinical use by physicians and general practitioners globally will be introduced from February 2027.
CAR-T therapy(Treatment for 18 types of Cancer) : the regulatory approval process is underway, with final clinical trials scheduled to begin in February 2027.
Gut microbiome testing: CDSCO approval received; commercial rollout from December 2027.
Building Capacity and Reach
Construction of the third IVD manufacturing facility has begun, and it is expected to be operational before March 2028. The company has also strengthened its core R&D team and INR 25 Crore till March 2028.
The institutional healthcare division served 10,000 customers, including hospitals. Over next two years we are targeting 25,000 customers including hospitals & labs in IVD division. Subsidiary Lord’s Mark Micro Biotech Limited has crossed 70 laboratories and collection centres across India, network will continue to grow and is expected 600 by March 2028, giving the group a wider diagnostics footprint and an advantage as principal raw material manufacturer.
Going Global: United States, United Kingdom and Caribbean
United States: US subsidiary Lords Mark Industries Inc. has been established to set up a dedicated laboratory and export the full range of IVD and surgical products from India. Sales are targeted from March 2027, following US FDA approval.
United Kingdom: The UK subsidiary has secured all necessary MHRA approvals for its range, including AI-based dialysis machines, which the company believes makes it one of the fastest to achieve this clearance. Sales from India will begin in January 2027 and UK operations in February 2027.
Caribbean: Pathology laboratories are being set up with local partners, with export sales targeted from March 2027.
Taking Indian CAR-T technology abroad: Lord’s Mark has begun the regulatory and clinical processes to bring its proprietary CAR-T cancer treatment technology to the US, UK and Europe, and aims to be the first Indian company to take this cellular therapy global. Trial reports are slated for publication by December 2027, with advanced treatment centers targeted for June 2028.
Outlook
With results scaling, approvals in hand across several products and international subsidiaries in place, Lord’s Mark is moving from building capability to commercializing it. Management’s priorities are to scale healthcare manufacturing, grow its institutional and diagnostics network, bring technology-led products to market and establish a lasting presence in the US, UK and other international markets. Between December 2026 and March 2028, a series of dated launches and capacity milestones will show how these investments translate into revenue.
About Lord’s Mark Industries Limited
Lord’s Mark Industries Limited (BSE: 501261; formerly Lords Mark India Limited / Kratos Energy & Infrastructure Limited) is a healthcare company with interests in medical device manufacturing, in-vitro diagnostics, pathology and diagnostics networks, institutional healthcare supply and advanced medical technologies. Its consolidated results include the accounts of Lords Mark Tech Next Private Limited, Lords Mark Micro Biotech Private Limited, Renalyx Health Systems Private Limited and Lords Green Energy Private Limited. Registered office: B-101, Riddhi Siddhi Complex, M.G. Road, Borivali (E), Mumbai 400066. CIN: L35103MH1979PLC021614. Website: www.lordsmark.com
Past performance does not guarantee future returns.
Disclaimer: The information provided in this article is for informational and educational purposes only. It does not constitute financial, legal, or investment advice. Readers should not rely on this content to make investment decisions. We strongly recommend consulting with a licensed financial advisor or conducting your own due diligence before making any financial commitments.